$IMUX News

Immunic Announces Presentation Of One Late-Breaking And Two Additional Posters Highlighting Additional Data From Its Phase 2 CALLIPER Trial

B. Riley Securities Maintains Buy on Immunic, Lowers Price Target to $27

Immunic Appoints Michael W. Bonney As Board Chairman

Immunic Q1 EPS $(1.08) Misses $(0.91) Estimate

Immunic: Saved By A 200 Million Private Placement

HC Wainwright & Co. Maintains Buy on Immunic, Raises Price Target to $22

Immunic Appoints New Medical Officer To Lead Clinical And Regulatory Strategy

Immunic Appoints Michael A. Panzara, M.D., M.P.H., as CMO

Immunic Appoints Michael A. Panzara, M.D., M.P.H., as CMO

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Immunic to implement 1-for-10 reverse stock split

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

Immunic Announces 1-For-10 Reverse Stock Split, Effective April 27

Stifel Initiates Coverage On Immunic with Buy Rating, Announces Price Target of $2.5

Immunic, Inc. (IMUX) Presents at 8th Annual Neuroimmunology Drug Development Summit - Slideshow

D. Boral Capital Downgrades Immunic to Hold

Immunic to Participate in Scientific and Medical Conferences in April

Immunic COO highlights the importance of science-led innovation to mark World Health Day

Immunic Files Prospectus To Offer Up To 458.2M Shares Of Common Stock By The Selling Stockholders